

April 9, 2024

Company Name: HEALIOS K.K.  
Representative: Hardy TS Kagimoto, Chairman & CEO  
(TSE Growth Code: 4593)  
Contact: Richard Kincaid, Executive Officer CFO  
(TEL: 03-4590-8009)

## **Joint Research Agreement with AND medical to Utilize Healios Technology and Culture Supernatant**

HEALIOS K.K. (“Healios”) today announces that it has entered into a Joint Research Agreement (the "Agreement") with AND medical group (“AND medical” <https://and-mg.com/>) to utilize Healios owned technology and culture supernatant.

Note: This agreement is based on the Letter of Intent announced on January 16, 2024 in the press release titled "[Announcement of Letter of Intent on Joint Research for Utilization of Culture Supernatant.](#)"

### **1. Outline of the Agreement**

The purpose of the Agreement is that Healios will provide regenerative medicine technology and raw materials to AND medical for use in the development of a new therapy. Upon entering of the agreement, Healios will receive 60 million yen as an upfront payment. Subsequently, the company will receive milestone payments based on the progress of the research, which together with the upfront payment will total 180 million yen. After the manufacturing method and system for the raw materials have been established and the objectives of the Agreement have been achieved, Healios expects to enter into an agreement to supply culture supernatant to AND Medical on an ongoing basis.

Tadahisa Kagimoto, MD, Chairman and CEO of Healios, made the following comment: “As our production of regenerative medicine products increases utilizing 3D culture methods, a large amount of various culture supernatants will be produced. We are pleased to announce the start of a Joint Research Agreement on the utilization of such raw materials. This activity is in line with our vision of ‘transforming the lives of patients by creating, developing and commercializing cutting edge cell therapy technologies.’ Furthermore, by generating sales as soon as possible, we aim to strengthen our financial position as well as effectively utilize our resources.”

### **2. Future Outlook**

The upfront payment of 60 million yen will be received in the second quarter of the fiscal year ending December 31, 2024. The upfront payment and milestone payments based on the progress of the research under the Agreement will be recorded as either income or expense deductions throughout the term of the collaboration. We will promptly announce any matters that should be disclosed in the future.

### **About AND medical group:**

AND medical group is a comprehensive medical group operating clinics in 22 locations nationwide (as of the end of March 2024). Established in 2020, the company offers cosmetic dermatology, cosmetic surgery, plastic surgery, and urology services, and has also begun

working in the field of regenerative medicine using stem cells at its affiliated regenerative medical institutions.

The company believes that there are various kinds of "beauty" depending on the different personalities, preferences, and values that each person possesses, and aims to provide various medical services to reduce patients' dissatisfaction and complexes about their appearance, aiming to realize "a world where everyone can pursue their own personal beauty", regardless of gender, age, or nationality.

In the future, we will advance joint research with Healios in the field of regenerative medicine. Together we will conduct scientific verification of safety and therapeutic efficacy at the level required by the government, aiming to establish stem cell-based therapeutic approaches and manufacture cosmetic as well as medical products utilizing cultures supernatants. By doing so, we aspire to explore the potential of stem cell therapy across various disease affected area.

Name of the company: AND medical group

Location: Roppongi, Minato-ku, Tokyo

Representative: Masaomi Kusano, Representative of Board of Directors

<https://and-mg.com/>

#### **About Healios:**

Healios K.K. is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells.

In the somatic stem cell field, Healios is developing MultiStem<sup>®</sup> (HLCM051), a proprietary cell product comprised of multipotent adult progenitor cells ("MAPCs") derived from the bone marrow of healthy adult donors. MultiStem has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in hundreds of patients across multiple indications. Healios is seeking to advance MultiStem on a global basis for ischemic stroke, ARDS, and trauma.

In the iPSC regenerative medicine field, Healios' lead candidate, HLCN061, is a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-editing. These cells have demonstrated robust anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process, and are currently being prepared for initial human testing. The company has also established a proprietary, gene-edited "universal donor" induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need.

Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593). <https://www.healios.co.jp/en>